Diplomat Pharmacy (DPLO) Releases Quarterly Earnings Results, Misses Estimates By $0.21 EPS

Diplomat Pharmacy (NYSE:DPLO) released its quarterly earnings data on Tuesday. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.21), Fidelity Earnings reports. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.42 billion. Diplomat Pharmacy had a return on equity of 5.33% and a net margin of 0.04%. The firm’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.01 earnings per share. Diplomat Pharmacy updated its FY18 guidance to $(0.10)-$0.03 EPS.

DPLO traded down $0.11 on Thursday, reaching $14.69. The company had a trading volume of 64,682 shares, compared to its average volume of 765,330. Diplomat Pharmacy has a fifty-two week low of $13.31 and a fifty-two week high of $28.74. The firm has a market cap of $1.51 billion, a P/E ratio of 17.46 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.63 and a current ratio of 0.91.

In related news, Director Philip R. Hagerman sold 209,367 shares of the company’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $19.07, for a total value of $3,992,628.69. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Philip R. Hagerman sold 57,500 shares of the company’s stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total transaction of $1,104,575.00. The disclosure for this sale can be found here. 24.70% of the stock is currently owned by corporate insiders.

DPLO has been the topic of several recent analyst reports. ValuEngine lowered shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Wednesday, September 12th. Zacks Investment Research lowered shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Tuesday, October 23rd. Robert W. Baird lowered shares of Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and decreased their price target for the company from $22.00 to $10.00 in a research note on Wednesday. Finally, Wells Fargo & Co decreased their price target on shares of Diplomat Pharmacy from $23.00 to $16.00 and set a “market perform” rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. Diplomat Pharmacy currently has an average rating of “Hold” and a consensus price target of $25.20.

TRADEMARK VIOLATION NOTICE: This news story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://sportsperspectives.com/2018/11/08/diplomat-pharmacy-dplo-releases-quarterly-earnings-results-misses-estimates-by-0-21-eps-2.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Read More: Balance Sheet

Earnings History for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply